News
IBI3030 significantly reduces LDL-c (p<0.01 vs. baseline) and Lp(a), improves oral glucose tolerance (OGTT) (effective even in GLP-1R knockout mice), reduces body weight, and preserves insulin ...
More than 90% of patients achieved clinically meaningful weight reduction compared to placebo in a phase 3 trial of ecnoglutide.
A novel weight loss drug in the same class as semaglutide has successfully met its targets in its largest clinical trial yet, ...
A common diabetes drug may be the next big thing for migraine relief. In a clinical study, obese patients with chronic ...
A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new ...
A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new ...
If you’re considering using medication to reach a healthy body weight, your first question might be: Are weight loss drugs covered by insurance? The short answer: Sometimes, but not always.
A recent study found that older adults with diabetes who use a GLP-1 drug have double the risk of developing wet age-related ...
Compounded vs non-compounded GLP-1 RA drug products are associated with an increased risk for adverse events such as nausea and diarrhea.
A new study reports that people taking GLP-1 drugs in daily life don’t lose as much weight as those in clinical trials who ...
GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.
A new obesity drug combining four hormones may outperform Wegovy and Mounjaro. Learn what it means for health, science, and investors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results